Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss

Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss at other companies

General Mills logo
General MillsGIS
$0—
Duke Energy logo
Duke EnergyDUK
$150M-19.8%
General Mills logo
General MillsGIS
$0—
Chimera Investment Corp. logo
Chimera Investment Corp.CIM
$113.09M-2.6%
Bank of America logo
Bank of AmericaBAC
$84.3B-15.6%
Wintrust Financial logo
Wintrust FinancialWTFC
$3.9M-45.9%

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss?
Ionis Pharmaceuticals (IONS) reported debt securities available for sale and equity securities fv ni gross unrealized loss of $12.54M in Q1 2026.
How has Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss changed year-over-year?
Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss decreased by 29.1% year-over-year, from $17.68M to $12.54M.
What is the long-term trend for Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss?
Over 5 years (2020 to 2025), Ionis Pharmaceuticals's debt securities available for sale and equity securities fv ni gross unrealized loss has grown at a 41.9% compound annual growth rate (CAGR), from $2.82M to $16.26M.
What does debt securities available for sale and equity securities fv ni gross unrealized loss mean?
The total paper loss across all debt and equity investments.
How do you interpret debt securities available for sale and equity securities fv ni gross unrealized loss?
An increase indicates declining market value across the investment portfolio, signaling potential risk or market headwinds.
How does debt securities available for sale and equity securities fv ni gross unrealized loss compare across companies?
Used to assess the sensitivity of the company's balance sheet to market volatility.